SCHEMBL3556174

SCHEMBL3556174

Cc1cc(-c2ccc(Cl)cc2)nc(-c2cccc(-c3ccc(S(=O)(=O)NC(C)(C)C)s3)c2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PFKFB4 Q16877 2/20 0.41
PFKFB3 Q16875 4/20 0.40
DRD2 P14416 1/20 0.39
HTR2C P28335 1/20 0.39
DRD3 P35462 1/20 0.39
HTR6 P50406 1/20 0.39
ADAMTS5 Q9UNA0 5/20 0.39
MMP1 P03956 1/20 0.39
MMP14 P50281 1/20 0.39
ADAM17 P78536 1/20 0.39
CNR1 P21554 1/20 0.37
KDM1A O60341 2/20 0.37
MAOA P21397 2/20 0.37
MAPT P10636 2/20 0.36
PRF1 P14222 1/20 0.36
GABRA1 P14867 1/20 0.36
TP53 P04637 1/20 0.36
EDNRB P24530 1/20 0.35
EDNRA P25101 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3557143 0.90 PFKFB4 (0.41) PFKFB4PFKFB3MAPTPRF1EDNRB
SCHEMBL3559394 0.89 PFKFB4 (0.39) PFKFB4PFKFB3ADAMTS5MAPTPRF1
SCHEMBL3561139 0.88 HSD17B10 (0.41) PFKFB4PFKFB3KDM1ATP53
SCHEMBL3560376 0.88 PFKFB3 (0.43) PFKFB4PFKFB3MMP1MAPT
SCHEMBL3562453 0.88 GABRA1 (0.41) PFKFB4PFKFB3DRD2HTR2CDRD3
SCHEMBL3573480 0.85 CA12 (0.47) PFKFB4PFKFB3CNR1
SCHEMBL2402449 0.84 PFKFB3 (0.38) PFKFB4PFKFB3PRF1
SCHEMBL3569000 0.84 PFKFB3 (0.38) PFKFB4PFKFB3MAPTPRF1
SCHEMBL3556987 0.83 JAK2 (0.47) KDM1AMAOAMAPT
SCHEMBL3563375 0.79 KDM4E (0.47) MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 PFKFB4 1245/4885PFKFB3 1222/4885DRD2 519/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 PFKFB4 546/4885PFKFB3 556/4885DRD2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.